Browsing: TNBC

A SEER analysis indicates adjuvant chemotherapy for triple-negative breast cancer offers a meaningful survival benefit even for older patients—particularly those…

A Chinese retrospective analysis classified 352 triple-negative breast cancers receiving post-mastectomy radiation into basal-like immune-suppressed (BLIS) and non-BLIS subtypes using…

In contrast to KEYNOTE-522 that established the addition of perioperative pembrolizumab to neoadjuvant chemo for triple-negative breast cancer improves survival,…

Perioperative chemo-immunotherapy with pembrolizumab improves the pathologic complete response rate and event free survival in patients with stage II and…

Top Line: Is surgery necessary for breast cancer patients who have a complete response to neoadjuvant therapy? The Study: Patients…